A total of 14 favorable announcements were filed by STAR Market companies today. These include one new share buyback plan from YanDong Microelectronics Co., Ltd. (688172) with an upper limit of 300 million yuan, and three companies — Kingsoft Office Software Co., Ltd. (688111), SanSec Information Technology Co., Ltd. (688489), and HyperStrong Co., Ltd. (688411) — submitting strong performance forecasts or preliminary results. The detailed positive news is as follows:

Kingsoft Office Software Co., Ltd. (688111): The company’s performance forecast shows a significant increase, driven by the continued development of its AI-native office capabilities and notable contributions from investment income from some external funds. It expects first-half 2026 revenue to be between 3.214 billion yuan and 3.413 billion yuan, up 20.95% to 28.43% year-on-year. Net profit attributable to shareholders is projected to be between 2.316 billion yuan and 2.719 billion yuan, a surge of 209.98% to 263.89%.

SanSec Information Technology Co., Ltd. (688489): The company’s performance forecast indicates a significant reduction in losses, thanks to a substantial increase in overseas market and cryptographic chip business scale, as well as the gradual implementation of projects in new areas like anti-quantum cryptography. It expects first-half 2026 revenue of 209.4478 million yuan, up 7.38% year-on-year. The net loss attributable to the parent company is projected at -12.5616 million yuan, narrowing by 57.25%.

HyperStrong Co., Ltd. (688411): The company expects a profit increase due to its global expansion in the energy storage business. It projects first-half 2026 revenue between 5.600 billion yuan and 6.900 billion yuan, representing a 23.83% to 52.58% year-on-year increase. Net profit attributable to shareholders is forecast to be between 620 million yuan and 700 million yuan, an increase of 96.30% to 121.63%.

Dameng Database Co., Ltd. (688692): A shareholder increased its holdings in the secondary market. On July 28, 2026, shareholder China Electronics Jintou Holdings Co., Ltd. purchased 11,758 shares of the company through centralized竞价 trading on the secondary market, representing a 0.01% increase in shareholding. After this change, China Electronics Jintou and its concert party, China Software, collectively hold 28,310,000 shares of the company, accounting for 25.00% of the total share capital.

Huitong New Material Co., Ltd. (688219): The company has completed share buybacks totaling 49.9952 million yuan. As of July 28, 2026, the company had repurchased 4.7951 million shares through centralized竞价 trading on the Shanghai Stock Exchange, accounting for 0.8725% of the total share capital. The total amount repurchased was 49.9952 million yuan (excluding transaction costs such as stamp duty and commissions).

Fumaomao Technology Co., Ltd. (688350): The company conducted its first share buyback of 8.3975 million yuan. On July 28, 2026, the company repurchased 298,800 shares for the first time through centralized竞价 trading on the Shanghai Stock Exchange, accounting for 0.21% of the total share capital. The buyback amount was 8.3975 million yuan (excluding transaction costs).

Huicheng Shares Co., Ltd. (688403): The company has completed share buybacks totaling 65.9987 million yuan. As of July 28, 2026, the company had repurchased 2.6469 million shares through centralized竞价 trading, accounting for 0.27% of the total share capital. The total buyback amount was 65.9987 million yuan (excluding transaction costs).

Atess Co., Ltd. (688472): The company has completed share buybacks totaling 192.6021 million yuan. As of July 28, 2026, the company had repurchased 19 million shares through centralized竞价 trading, accounting for 0.52% of the total share capital. The total buyback amount was 192.6021 million yuan (excluding transaction costs).

Geling Shenzhen Co., Ltd. (688207): The company has completed share buybacks totaling 24.8044 million yuan. As of July 28, 2026, the company had repurchased 1.6108 million shares through centralized竞价 trading, accounting for 0.62% of the total share capital. The highest repurchase price was 15.70 yuan per share, and the lowest was 14.95 yuan per share. The total amount of funds paid was 24.8044 million yuan (excluding transaction costs).

Zhengyuan Dixin Co., Ltd. (688509): The controlling shareholder has voluntarily extended the lock-up period. The company’s controlling shareholder, China Metallurgical Geology Bureau, has voluntarily extended the lock-up period for its pre-IPO shares by an additional 12 months, until July 30, 2027. The number of shares subject to this extended lock-up is 385,207,800, representing 50.03% of the company’s total share capital.

Shanghai Yizhong Co., Ltd. (688091): The company has completed share buybacks totaling 24.9915 million yuan. As of July 28, 2026, the company had repurchased 645,345 shares, accounting for 0.31% of the total 206,703,640 shares. The buyback amount was 24,991,543.25 yuan.

Aike Saibo Co., Ltd. (688719): The company has completed share buybacks totaling 34.5648 million yuan. As of July 28, 2026, the company had repurchased 726,182 shares, accounting for 0.63% of the total share capital. The buyback amount was 34.5648 million yuan.

[The following announcements have not yet been listed online.]

YanDong Microelectronics Co., Ltd. (688172): The actual controller plans to increase holdings by 150 million to 300 million yuan. The company’s controlling shareholder and a concert party of the actual controller, Beijing Electronics Holdings Industry Investment Co., Ltd., based on confidence in the company’s future stable development and recognition of its long-term investment value, intends to increase its holdings in the company through centralized竞价 trading on the Shanghai Stock Exchange within 12 months from the date of this announcement. The total proposed increase is not less than 150 million yuan and not more than 300 million yuan.

Sunshine Noah Co., Ltd. (688621): The company has received a drug clinical trial approval notice. The company’s wholly-owned subsidiary, Chengdu Nuohao Shengtai Biotechnology Co., Ltd., has received a “Drug Clinical Trial Approval Notice” from the National Medical Products Administration. The clinical trial application for the company’s in-house Class 1 innovative drug, STC009 injection, has been approved.